NASDAQ
0.22USD
-0.01 (-3.54%)
We have scored 8 news catalysts on Accuray Incorporated (ARAY) over the past 12 months. The biggest single-day move next to one of them came May 15, 2026, when ARAY closed −5.2%: “Accuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with Cancer”. Coverage across the window leans positive (average ticker sentiment +0.21). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
25.6M
P/E
—
EPS
—
Beta
1.39
52W range
0.2151-2.1
Day range
0.22–0.23
Open
0.23
Prev close
0.22
Volume
760.5K
Avg volume
2.7M
Dividend
0.00
IPO
2007-02-08
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Accuray Incorporated — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ARAY: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
